PL3639845T3 - Kompozycja farmaceutyczna zawierająca kompleks białka il-15 i jej zastosowania - Google Patents

Kompozycja farmaceutyczna zawierająca kompleks białka il-15 i jej zastosowania

Info

Publication number
PL3639845T3
PL3639845T3 PL18838766.6T PL18838766T PL3639845T3 PL 3639845 T3 PL3639845 T3 PL 3639845T3 PL 18838766 T PL18838766 T PL 18838766T PL 3639845 T3 PL3639845 T3 PL 3639845T3
Authority
PL
Poland
Prior art keywords
pharmaceutical composition
protein complex
complex pharmaceutical
protein
composition
Prior art date
Application number
PL18838766.6T
Other languages
English (en)
Inventor
Tingting Wu
Hao Li
Xun Liu
Original Assignee
Jiangsu Hengrui Medicine Co., Ltd.
Shanghai Hengrui Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd. filed Critical Jiangsu Hengrui Medicine Co., Ltd.
Publication of PL3639845T3 publication Critical patent/PL3639845T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL18838766.6T 2017-07-25 2018-07-24 Kompozycja farmaceutyczna zawierająca kompleks białka il-15 i jej zastosowania PL3639845T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710611317 2017-07-25
PCT/CN2018/096775 WO2019019998A1 (zh) 2017-07-25 2018-07-24 一种il-15蛋白复合物药物组合物及其用途

Publications (1)

Publication Number Publication Date
PL3639845T3 true PL3639845T3 (pl) 2023-10-23

Family

ID=65041144

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18838766.6T PL3639845T3 (pl) 2017-07-25 2018-07-24 Kompozycja farmaceutyczna zawierająca kompleks białka il-15 i jej zastosowania

Country Status (15)

Country Link
US (1) US11273205B2 (pl)
EP (1) EP3639845B1 (pl)
JP (1) JP7263312B2 (pl)
KR (1) KR102720834B1 (pl)
CN (1) CN109963581B (pl)
AU (1) AU2018308773B2 (pl)
BR (1) BR112020001101A2 (pl)
CA (1) CA3070016A1 (pl)
ES (1) ES2950570T3 (pl)
PL (1) PL3639845T3 (pl)
RU (1) RU2749342C1 (pl)
TW (1) TWI810196B (pl)
UA (1) UA125971C2 (pl)
WO (1) WO2019019998A1 (pl)
ZA (1) ZA201908610B (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070157228A1 (en) 2005-12-30 2007-07-05 Jason Bayer Advertising with video ad creatives
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
IL297326A (en) * 2020-04-22 2022-12-01 Novartis Ag Pharmaceutical preparations and pharmaceutical products of human interleukin-15 hydrometers (ethyl-15)
CA3172871A1 (en) * 2020-05-11 2021-11-18 Francisca O. GBORMITTAH Il-2 fusion polypeptide compositions and methods of making and using the same
CN115867307A (zh) * 2020-05-11 2023-03-28 奥克梅斯制药爱尔兰有限公司 Il-2融合多肽组合物以及其制备和使用方法
EP4395816A4 (en) * 2021-09-03 2025-07-30 Dr Reddys Laboratories Ltd PHARMACEUTICAL FORMULATION OF IMMUNE CHECKPOINT INHIBITORS
EP4395815A4 (en) * 2021-09-03 2025-07-30 Dr Reddys Laboratories Ltd METHOD FOR IMPROVING THE STABILITY OF IMMUNE CHECKPOINT INHIBITORS
EP4434998A4 (en) * 2021-11-18 2025-06-18 Shandong Simcere Biopharmaceutical Co., Ltd. PHARMACEUTICAL COMPOSITION OF IL-15 MUTANT FUSION PROTEIN
CN121949562A (zh) * 2024-10-30 2026-05-01 钱杭江医药科技(嘉兴)有限公司 一种新型蛋白复合物的二聚体化合物及其制备方法和制药用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA966075B (en) * 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
CN100334112C (zh) * 2004-10-15 2007-08-29 上海海欣生物技术有限公司 人白细胞介素15与Fc融合蛋白
HUE034109T2 (en) * 2005-03-25 2018-01-29 Regeneron Pharma VEGF antagonist formulations
PL1899364T5 (pl) 2005-05-17 2024-12-09 University Of Connecticut Kompozycje i sposoby immunomodulacji w organizmie
US20070160578A1 (en) 2005-12-14 2007-07-12 The Gov. Of The Usa As Represented By The Secretary Of The Dep. Of Health And Human Services Expansion of natural killer and CD8 T-cells with IL-15R/ligand activator complexes
WO2008086395A2 (en) * 2007-01-09 2008-07-17 Wyeth Anti-il-13 antibody formulations and uses thereof
AU2013203204B2 (en) * 2007-06-27 2016-05-19 Novartis Ag Complexes of il-15 and il-15r.alpha and uses thereof
KR20210054598A (ko) * 2009-09-21 2021-05-13 다케다 야쿠힌 고교 가부시키가이샤 안정화된 액체 및 동결건조된 ａｄａｍｔｓ13 제제
CN101735982A (zh) 2009-12-31 2010-06-16 浙江中赢控股集团有限公司 白介素15受体-白介素2复合物扩增淋巴细胞的方法
EP2619229B1 (en) 2010-09-21 2016-04-06 Altor BioScience Corporation Multimeric il-15 soluble fusion molecules and methods of making and using same
WO2014066527A2 (en) * 2012-10-24 2014-05-01 Admune Therapeutics Llc Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
AU2014377106B2 (en) * 2014-01-08 2019-10-03 Jiangsu Hengrui Medicine Co., Ltd. IL-15 heterodimeric protein and uses thereof
CN105708811A (zh) * 2014-12-01 2016-06-29 西藏海思科药业集团股份有限公司 一种稳定的重组人抗cd20单克隆抗体的冻干制剂
LT3235830T (lt) 2014-12-19 2020-12-28 Jiangsu Hengrui Medicine Co., Ltd. Interleukino 15 baltymų kompleksas ir jo naudojimas
MX395336B (es) * 2015-09-28 2025-03-25 Suzhou Suncadia Biopharmaceuticals Co Ltd Preparacion farmaceutica de anticuerpo anti-pd-1 estable y aplicacion del mismo en medicina.
MX2018007304A (es) * 2015-12-21 2019-03-14 Armo Biosciences Inc Composiciones de interleucina-15 y sus usos.

Also Published As

Publication number Publication date
CA3070016A1 (en) 2019-01-31
TWI810196B (zh) 2023-08-01
CN109963581A (zh) 2019-07-02
JP2020528424A (ja) 2020-09-24
EP3639845A4 (en) 2020-06-10
CN109963581B (zh) 2023-09-19
BR112020001101A2 (pt) 2020-07-21
EP3639845B1 (en) 2023-06-21
ZA201908610B (en) 2023-10-25
KR20200033265A (ko) 2020-03-27
AU2018308773B2 (en) 2024-12-05
JP7263312B2 (ja) 2023-04-24
AU2018308773A1 (en) 2020-01-16
EP3639845A1 (en) 2020-04-22
WO2019019998A1 (zh) 2019-01-31
RU2749342C1 (ru) 2021-06-08
US20200230210A1 (en) 2020-07-23
KR102720834B1 (ko) 2024-10-23
UA125971C2 (uk) 2022-07-20
ES2950570T3 (es) 2023-10-11
US11273205B2 (en) 2022-03-15
TW201907947A (zh) 2019-03-01
EP3639845C0 (en) 2023-06-21

Similar Documents

Publication Publication Date Title
IL273432A (en) Protein compounds and their uses
ZA201802003B (en) Dual function proteins and pharmaceutical composition comprising same
ZA201802125B (en) Pharmaceutical composition and application thereof
SI3235830T1 (sl) Proteinski kompleks interlevkina 15 in njegove uporabe
IL274809A (en) Antibodies against CXCR5 and their preparations and uses
ZA201900209B (en) Novel natural protein and application thereof
SMT202500440T1 (it) Composizione liposomiale e composizione farmaceutica
IL265796A (en) Preparations comprising short peptides derived from pedf and their uses
PL3405222T3 (pl) Nowe polipeptydy i ich zastosowania medyczne
PT3159344T (pt) Derivado em anel aminopiranoide e sua composição e utilização
ZA202000238B (en) Sost antibody pharmaceutical composition and uses thereof
GB201707248D0 (en) Modified complement proteins and uses thereof
IL272050A (en) Synthetic proteins and their therapeutic uses
GB2546439B (en) Ezrin-derived peptides and pharmaceutical compositions thereof
SG11202002224XA (en) Composition and uses thereof
EP3647325A4 (en) PHARMACEUTICAL COMPOSITION OF PCSK-9 ANTIBODIES AND USES THEREOF
ZA202100166B (en) Composition comprising glycyrrhin and cosmetic and pharmaceutical uses thereof
HUP1700012A2 (en) Novel proteins and use thereof
ZA201903341B (en) Pharmaceutical compositions and uses thereof
GB201713920D0 (en) Pharmaceutical compositions and uses thereof
GB201712268D0 (en) Polypeptides and uses thereof
GB201712266D0 (en) polypeptides and uses thereof
GB201617925D0 (en) Proteins and uses
HK1246094A1 (en) Milk-based protein hydrolysates and composition made thereof